Trader’s Alert – Dyax Corp, Boeing, Tyco
Dyax Corp (NASDAQ:DYAX) shares rose 8.1% to $10.99, their highest price since mid-2004, after positive Phase 1a study results of DX-2930, a treatment for hereditary angioedema attacks. The first-in-human clinical study of DX-2930 met all objectives of assessing safety, tolerability and pharmacokinetics and showed it well tolerated at all dose levels. Pharmacokinetic results demonstrated that…
